Current Report Filing (8-k)
August 15 2022 - 04:21PM
Edgar (US Regulatory)
0001035354 false 0001035354 2022-08-15
2022-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 15, 2022
Eloxx Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-31326 |
|
84-1368850 |
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
480 Arsenal Way, Suite 130,
Watertown,
MA
|
|
02451 |
| (Address of principal
executive offices) |
|
(Zip
Code) |
(Registrant’s telephone number, including area code): (781)
577-5300
N/A
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each
class |
Trading
Symbol(s) |
Name of
each exchange on which registered |
|
Common Stock, $0.01 par value per share |
ELOX |
The
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
|
Item 2.02 |
Results of Operations and Financial Condition. |
On August 15, 2022, Eloxx Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing its financial results for the
quarterly period ended June 30, 2022 and providing a business
update. A copy of the Company’s press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
The information in this Current Report on Form 8-K, including the
information contained in the press release furnished as Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or the Exchange Act,
or otherwise subject to the liabilities of that section, and shall
not be deemed incorporated by reference into any of the Company’s
filings under the Securities Act of 1933, as amended or the
Exchange Act, whether made before or after the date hereof,
regardless of any general incorporation language in such filing,
except as shall be expressly set forth by specific reference in
such filing.
|
Item
9.01 |
Financial Statements and
Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Date:
August 15, 2022 |
ELOXX PHARMACEUTICALS, INC.
|
| |
|
| |
By: |
/s/ Sumit
Aggarwal |
| |
Name: Sumit Aggarwal |
| |
Title: President and Chief Executive Officer |
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Feb 2023 to Mar 2023
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2022 to Mar 2023
